PDCD1 and neoplasm: In the phase-I AMBER study (NCT02817633), cobolimab is being tested as a monotherapy or in combination with nivolumab or dostarlimab (anti-PD-1) in patients with advanced solid malignancies; preliminary evidence shows anti-tumor activity and a manageable safety profile [98].